Aptose Biosciences Inc (APS_TSE)
APS_TSE moved a median of 0.00% 30 minutes after news, and -2.60% by the close. How APS_TSE actually reacts to news — the realized, point-in-time move the market made, measured across 110 labeled events over the last three years with zero look-ahead.
APS_TSE’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 5% | 22 |
| 30-min | 0.00% | 23% | 22 |
| 60-min | -0.49% | 32% | 22 |
| to close | -2.60% | 32% | 22 |
| Middle 50% of APS_TSE reactions | -4.45% to 0.00% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 110 |
Half of all Aptose Biosciences Inc news events land between -4.45% and +0.00% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when APS_TSE moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to APS_TSE's baseline. Nothing else.
Recent APS_TSE events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Aptose Biosciences Announces Completion of Acquisition by Hanmi Pharmaceutical | Press release | GlobeNewswire | — | — | |
| Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2026 EHA Congress in Oral Presentation | Press release | GlobeNewswire | — | — | |
| Aptose Biosciences Announces Update on Anticipated Timing of Closing of the Plan of Arrangement with Hanmi Pharmaceutical | Press release | GlobeNewswire | — | — | |
| Aptose Reports First Quarter 2026 Results | Press release | GlobeNewswire | — | — | |
| Aptose Biosciences Announces Update on Anticipated Timing of Closing of the Plan of Arrangement with Hanmi Pharmaceutical | Press release | GlobeNewswire | — | — | |
| Aptose Biosciences Announces Results of Special Shareholders Meeting; Announces Receipt of Final Court Approval of Plan of Arrangement; Reports Year End 2025 Results and Corporate Highlights | Press release | GlobeNewswire | — | — | |
| Leading Independent Proxy Advisory Firm Glass Lewis Endorses Aptose Plan of Arrangement | Press release | GlobeNewswire | — | — | |
| Leading Independent Proxy Advisory Firm ISS Recommends Aptose Biosciences Shareholders Vote “FOR” Proposed Plan of Arrangement with Hanmi Pharmaceutical | Press release | GlobeNewswire | — | — | |
| Aptose Biosciences Announces Amendment to Arrangement Agreement and Details of Postponed Special Meeting of Shareholders | Press release | GlobeNewswire | — | — | |
| Aptose Biosciences Announces Rescheduling of Special Meeting of Shareholders to Approve the Acquisition by Hanmi Pending Final Clearance from SEC | Press release | GlobeNewswire | — | — | |
| Form 8-K Aptose Biosciences Inc. For: Dec 06 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Aptose’s Tuspetinib Triple Drug Therapy Featured at the 2025 ASH Annual Meeting; High Rate of Frontline Clinical Responses Continues Across AML Populations | Press release | GlobeNewswire | — | — | |
| Form PREM14A Aptose Biosciences Inc. For: Jan 16 | SEC filing · Form PREM14A | SEC EDGAR | — | — | |
| Form 8-K Aptose Biosciences Inc. For: Nov 18 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Aptose Biosciences Announces Arrangement Agreement for Acquisition by Hanmi Pharmaceutical | Press release | GlobeNewswire | — | — | |
| Form 8-K Aptose Biosciences Inc. For: Nov 19 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Aptose Tuspetinib Clinical Data from Ongoing TUSCANY Trial in Newly Diagnosed AML Selected for Presentation at the 2025 ASH Annual Meeting | Press release | GlobeNewswire | — | — | |
| Form 8-K Aptose Biosciences Inc. For: Nov 03 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Aptose’s Tuspetinib Exceeds Expectations When Combined with Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML | Press release | GlobeNewswire | — | — | |
| Form 8-K Aptose Biosciences Inc. For: Oct 16 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Aptose and Hanmi Pharmaceutical Extend Loan Agreement to Continue Development of Tuspetinib in Triplet Therapy for AML | Press release | GlobeNewswire | — | — | |
| Form 8-K Aptose Biosciences Inc. For: Sep 22 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form 8-K Aptose Biosciences Inc. For: Aug 19 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form 8-K Aptose Biosciences Inc. For: Aug 22 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form 8-K Aptose Biosciences Inc. For: Aug 22 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Aptose Biosciences Announces Results of Reconvened Annual and Special Shareholders Meeting and Appointment of Ernst & Young LLP as New Auditor | Press release | GlobeNewswire | — | — | |
| Form 8-K Aptose Biosciences Inc. For: Aug 22 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Aptose Reports Early Data Demonstrating Tuspetinib Improves Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML in Phase 1/2 TUSCANY Trial | Press release | GlobeNewswire | — | — | |
| Form 8-K Aptose Biosciences Inc. For: Aug 18 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Aptose Reports Second Quarter 2025 Results | Press release | GlobeNewswire | — | — | |
| Form 10-Q Aptose Biosciences Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | — | — | |
| Form 8-K Aptose Biosciences Inc. For: Aug 13 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Aptose Enrollment is Open for 160 mg Dosing Cohort of Tuspetinib in Phase 1/2 TUSCANY Trial of Frontline Triple Drug Therapy | Press release | GlobeNewswire | — | — | |
| Form 8-K Aptose Biosciences Inc. For: Aug 06 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Aptose Selects Ernst & Young Global Limited as its New Independent Auditor and Calls Reconvened Meeting of its Shareholders | Press release | GlobeNewswire | — | — | |
| Form DEFA14A Aptose Biosciences Inc. | SEC filing · Form DEFA14A | SEC EDGAR | — | — | |
| Aptose Receives Second Advance under the Loan Agreement with Hanmi Pharmaceutical to Continue Development of Tuspetinib in Triplet Therapy for AML | Press release | GlobeNewswire | — | — | |
| Form 8-K Aptose Biosciences Inc. For: Jul 15 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form 8-K Aptose Biosciences Inc. For: Jun 24 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Aptose Upgraded to Trade on OTCQB Market | Press release | GlobeNewswire | — | — | |
| Form 8-K Aptose Biosciences Inc. For: Jul 01 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Aptose Announces Deferral of Interest Payment | Press release | GlobeNewswire | — | — | |
| Form 8-K Aptose Biosciences Inc. For: Jun 20 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Aptose and Hanmi Enter New Loan Agreement to Advance Development of Tuspetinib in Triplet Therapy for AML | Press release | GlobeNewswire | — | — | |
| Form 8-K Aptose Biosciences Inc. For: Jun 20 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form 8-K Aptose Biosciences Inc. For: Jun 16 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Aptose Provides Corporate Updates | Press release | GlobeNewswire | — | — | |
| Form 8-K Aptose Biosciences Inc. For: Jun 17 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2025 EHA Congress | Press release | GlobeNewswire | — | — | |
| Form 8-K Aptose Biosciences Inc. For: Jun 12 | SEC filing · Form 8-K | SEC EDGAR | — | — |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the APS_TSE section they belong to.
Where else APS_TSE is measured.
APS_TSE earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| EVOFEM BIOSCIENCE INC (EVFM) | 111 | 0.00% | 29% |
| Synlogic, Inc. (SYBX) | 111 | +0.29% | 53% |
| DYNATRONICS CORP (DYNT) | 110 | 0.00% | 30% |
| Mirati Therapeutics, Inc. (MRTX) | 109 | +0.11% | 81% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Aptose Biosciences Inc's median reaction calculated?
Every labeled APS_TSE news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 110 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 23% of APS_TSE's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does APS_TSE's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.